CN101608176A - 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 - Google Patents
姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 Download PDFInfo
- Publication number
- CN101608176A CN101608176A CNA200910094685XA CN200910094685A CN101608176A CN 101608176 A CN101608176 A CN 101608176A CN A200910094685X A CNA200910094685X A CN A200910094685XA CN 200910094685 A CN200910094685 A CN 200910094685A CN 101608176 A CN101608176 A CN 101608176A
- Authority
- CN
- China
- Prior art keywords
- tabfiblysin
- yao
- gene
- protease
- horsefly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 21
- 102000008946 Fibrinogen Human genes 0.000 title abstract description 10
- 108010049003 Fibrinogen Proteins 0.000 title abstract description 10
- 229940012952 fibrinogen Drugs 0.000 title abstract description 10
- 210000003079 salivary gland Anatomy 0.000 claims abstract description 19
- 108091005804 Peptidases Proteins 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 241000255632 Tabanus atratus Species 0.000 claims description 28
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 6
- 241000208474 Protea Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 description 15
- 241000239444 Tabanus yao Species 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 108090000604 Hydrolases Proteins 0.000 description 5
- 102000004157 Hydrolases Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000255628 Tabanidae Species 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001239 fibrinogenlytic effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000410394 Odorrana grahami Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102220004457 rs11567847 Human genes 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及一种姚虻唾液腺蛋白酶tabfiblysin及其基因和应用,属于生物医学技术领域。本发明的姚虻蛋白酶tabfiblysin是从姚虻唾液腺中分离得到的一种活性蛋白质,分子量27145.5道尔顿,其全序列由255个氨基酸组成;姚虻蛋白酶tabfiblysin基因由871个核苷酸组成。本发明的姚虻唾液腺蛋白酶tabfiblysin具有显著的水解纤维蛋白原和抑制血小板聚集的作用,能作为制备治疗血栓性疾病药物的应用。
Description
技术领域:
本发明提供一种姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用,属于生物医学技术领域。
背景技术:
血栓性疾病是一类严重影响人类健康的疾病,尤其是心脑血管血栓栓塞性疾病,已成为我国人口死亡的首要原因。及时给予抗栓药物,可大大提高病人的存活率,减轻脏器损害的程度和范围。抗栓药物主要包括溶栓药、抗凝药和抗血小板药。现有的抗凝药和抗血小板药存在着出血、血小板减少及停药后反弹等副作用。因此,人们正在积极寻找着各种生物来源的高效、特异、低毒的新型抗栓药物。
虻科昆虫俗称牛虻(horsefly),隶属于节肢动物门双翅目短角亚目虻科,是重要的医学和兽医学昆虫。其成虫是一种中药材,俗称虻虫,具有活血化瘀,破积痛经的功效。其药用历史悠久,能为开发现代新药提供靶标和启示。与此同时,传统中药药物成分的复杂性及其炮制方法的局限性造成药物活性成分不能更好的发挥作用,因而从这些传统药物中寻找特定的活性单体化合物是中药现代化的重要内容之一。
经文献检索,未见与本发明相同的公开报道。
发明内容:
本发明的目的旨在现有技术的基础上,提供一种姚虻纤维蛋白原水解酶及其基因和应用本发明的技术方案为:
姚虻蛋白酶tabfiblysin是我们首次从姚虻唾液腺中分离得到的一种活性蛋白质,分子量27145.5道尔顿。其全序列一级结构为:
MTSIPVSSFLLAALVLQYATSDAVNYCRLPCRGDNYHVGCGEPAYAQECGQSPRTRELL
KEHRNEILSKINDVRDHVAKGSWGLPVAARMKVVVWDAELAGLAKRHTKGCVGETHACRN
TERFWLPGQLNFKYSGDKLPRIKELIDDAVKKGHLQKHNITREIIGNYRENGPNGDVKEL
ALAISDRVTAVGCGLTTWQDGAKARALLTCNFSSQNTRGRPVYKIGNSPGEKCIEKDETY
KNLCPATEPIDPNKSN
姚虻唾液腺蛋白酶tabfiblysin基因的克隆包括:姚虻唾液腺总RNA提取,mRNA纯化,mRNA反转录及cDNA文库构建,设计引物,利用PCR方法筛选编码基因。基因测序结果表明编码唾液腺蛋白酶tabfiblysin基因由870个核苷酸组成,自5’端至3’端序列为:
atgacttccataccggtgtccagctttttacttgcggccttagtactacaatacgccact 60
agcgacgcagttaactactgtagattgccttgtcgaggggataattaccatgtgggctgt 120
ggtgagccagcgtatgcccaggaatgtgggcaaagtccaagaactcgcgagttattgaag 180
gagcatagaaatgagattttgtcgaagatcaacgatgtgcgagaccatgtggccaaggga 240
tcatggggactaccagtggcagcccgaatgaaagttgttgtatgggatgcggaactcgct 300
ggtttagccaaacgacatacaaagggatgcgttggagagacacatgcgtgtcgaaacaca 360
gaacgtttctggttgccaggtcaactaaacttcaaatactccggcgacaagctaccccgc 420
attaaggaacttattgatgatgctgtcaaaaaaggccacttgcagaagcataatattacg 480
agagaaattatagggaactatagggagaatggacctaatggggatgtcaaggaacttgcc 540
ttggccatatctgatcgagtcaccgccgttggctgcggactaactacttggcaggatgga 600
gcaaaggctcgcgcacttcttacgtgtaacttctcctcgcagaacactcggggtcgacct 660
gtctacaaaatcggcaatagtcctggcgaaaagtgcatcgagaaggatgaaacgtataaa 720
aacttgtgccctgctactgaacctatcgaccctaataagtctaactagcgtcatgtatct 780
atgtatataaataaaattgaagtgtctgtctgtaatataaaacaactgtcacttattgag 840
cgcaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 870
本发明的姚虻唾液腺蛋白酶tabfiblysin具有显著的水解纤维蛋白原和抑制血小板聚集的作用,能作为制备治疗血栓性疾病药物的被应用。
附图说明:
图1为本发明的分子筛分离图。图中箭头所示为活性峰。
图2为本发明姚虻的水解纤维蛋白原作用结果图。
图3为本发明抑制血小板聚集作用的结果图。
具体实施方式:
实施例一:姚虻唾液腺蛋白酶tabfiblysin基因的克隆:
一、姚虻唾液腺总RNA提取:
A.活体解剖姚虻,挑取唾液腺立即放入液氮中,迅速取一定量(0.5-2mg)唾液腺组织,加入已预冷的Trizol提取缓冲液(美国Invitrogen公司产品),置于冰上匀浆15分钟。
B.加入Trizol 1/5体积的氯仿,剧烈混匀约15秒,室温放置5分钟,4℃,12000rpm离心10分钟,取上清。
C.上清加入等体积的异丙醇,室温放置10分钟,4℃,12000rpm离心10分钟,沉淀用75%乙醇洗一次,晾干,管底沉淀物即为姚虻唾液腺总RNA。
二、姚虻唾液腺mRNA的纯化:
A.取姚虻唾液腺总RNA 500μg溶于500μl DEPC水中,65℃水浴10分钟,加人3μl的Oligo(dT)探针和13μl 20×SSC溶液,混匀,放置室温冷却,称为A液。
B.磁珠(SA-PMP)的洗涤:将磁珠轻弹混匀,至磁力架吸附30秒,弃上清,加0.5×SSC300μl,至磁力架吸附30秒,最后加100μl 0.5×SSC悬浮,称之为B液。
C.将A液加入B液中,室温放置10分钟,至磁力架吸附30秒,弃上清,用0.1×SSC洗涤4次,最后弃上清,加100μl DEPC水悬浮,至磁力架上吸附30秒,将上清移至新的试管,再加入150μl DEPC水重悬,至磁力架吸附30秒,移上清至上述试管,即为纯化的姚虻唾液腺mRNA。
D.加入1/10体积3M乙酸钠,pH5.2,等体积异丙醇,于-70℃放置30分钟,4℃,12000rpm离心10分钟,弃上清,沉淀溶解于10μl DEPC水中。
三、姚虻唾液腺cDNA文库构建:采用CLONTECH公司CreatorTM SMARTTM cDNALibrary Construction Kit质粒cDNA文库构建试剂盒。
A.cDNA第一链合成(mRNA反转录):
1.在无菌PCR管加入1μl姚虻唾液腺mRNA、1μl SMART IV引物、1μlCDS III/3’PCR引物,加2μl去离子水使总体积达到5μl。
2.混匀并短暂离心,72℃保温2分钟。
3.将离心管在冰上孵育2分钟。
4.在离心管中加入以下试剂2.0μl 5×第一链缓冲、1.0μl 20mMDTT、1.0μl 10mM dNTP混合物、1.0μl PowerScript逆转录酶。
5.混合离心管中试剂并短暂离心,在42℃保温1小时。
6.将离心管置于冰上中止第一链的合成。
7.从离心管取2μl所合成的cDNA第一链备用。
B.采用长末端聚合酶链式反应(LD-PCR)方法扩增第二链
1、95℃预热PCR仪。
2、将2μl cDNA第一链(mRNA反转录)、80μl去离子水、10μl 10×Advantage 2PCR缓冲、2μl 50×dNTP混合物、2μl 5’PCR引物、2μl CDS III/3’PCR引物以及2μl大肠杆菌聚合酶离心管进行反应。
3、在PCR仪中按以下程序扩增:95℃,20秒钟;22个循环:95℃,5秒钟,68℃,6分钟。
4、循环结束后,将离心管中合成的cDNA双链进行抽提。
C.大肠杆菌DH5α感受态细胞的制备:
1.挑取单个DH5α菌落,接种于3ml不含氨苄青霉素的LB培养基中,37℃培养过夜,次日取上述菌液按比例1∶100再接种于50ml LB培养液中,37℃振荡2小时。当OD600值达到0.35时,收获细菌培养物。冰浴10min,于4℃以5000rpm离心10min,以回收细胞。
2.每ml初始培养液加600ul预冷的0.1mol/LCaCl2-MgCl2溶液重悬。
3.于4℃以5000rpm离心10min,以回收细胞。
4.每ml初始培养液加60ul预冷的0.1mol/L CaCl2重悬细胞沉淀,分装后备用。
D.酶切、连接以及连接产物的转化:
1.在微量离心管中加入1μl Takara pMD19-T载体、4μl无指盘臭蛙cDNA双链溶液,全量为5μl。
2.加入5μl(等量)的连接酶缓冲混合物。
3.16℃反应2小时。
4.全量(10μl)加入至100μl DH5α感受态细胞中,冰浴30分钟。
5.42℃加热90秒钟后,再在冰中放置1分钟。
6.加入37℃温浴过的LB培养基900μl,37℃缓慢振荡培养60分钟。
7.取200μl涂布于含有X-Gal、IPTG、Amp的LB培养基上37℃培养16小时,形成单菌落。
8.每个LB平皿用5ml LB液体培养基洗涤菌落,加30%甘油冻存。构建的cDNA大约含1×106个单独克隆。
四、姚虻唾液腺蛋白酶tabfiblysin基因序列测定和结果:
根据分离纯化所得姚虻蛋白酶tabfiblysin的内肽氨基酸序列和双翅目昆虫密码子的偏嗜性,我们设计了一条简并引物NT3-F21,与构建姚虻唾液腺cDNA文库时所使用的接头引物CDSIII配对,正反向引物序列为:
NT3-F21:5’-Tac tcc gg(g/c)gac aa(a/g)ct(g/a)cc(c/g)cgc-3’;
CDSIII-primer:5’-att cta gag gcc gag gcg gcc atg-3’
以NT3-F21和3’PCR为引物,在我们已经构建好的姚虻唾液腺cDNA文库中筛选插入了编码tabfiblysin的cDNA序列的克隆。
根据测得的成熟蛋白的核苷酸序列设计反向引物和所构建的cDNA文库克隆的5’端保守序列为正向引物,正反向引物序列分别为:
5’primer:5’-aag cag tgg tat caa cgc aga gt-3’
NT3-R21:5’-(c/g)gg(t/c)ag(c/t)tt gtc(g/c)cc gga gta-3’
以我们所构建的姚虻唾液腺cDNA为模板,进行PCR。所获阳性单克隆核苷酸序列测定。测序结果表明编码tabfiblysin的cDNA序列由871个核苷酸组成,自5’端至3’端序列为:
atgacttccataccggtgtccagctttttacttgcggccttagtactacaatacgcc
M T S I P V S S F L L A A L V L Q Y A
actagcgacgcagttaactactgtagattgccttgtcgaggggataattaccatgtgggc
T S D A V N Y C R L P C R G D N Y H V G
tgtggtgagccagcgtatgcccaggaatgtgggcaaagtccaagaactcgcgagttattg
C G E P A Y A Q E C G Q S P R T R E L L
aaggagcatagaaatgagattttgtcgaagatcaacgatgtgcgagaccatgtggccaag
K E H R N E I L S K I N D V R D H V A K
ggatcatggggactaccagtggcagcccgaatgaaagttgttgtatgggatgcggaactc
G S W G L P V A A R M K V V V W D A E L
gctggtttagccaaacgacatacaaagggatgcgttggagagacacatgcgtgtcgaaac
A G L A K R H T K G C V G E T H A C R N
acagaacgtttctggttgccaggtcaactaaacttcaaatactccggcgacaagctaccc
T E R F W L P G Q L N F K Y S G D K L P
cgcattaaggaacttattgatgatgctgtcaaaaaaggccacttgcagaagcataatatt
R I K E L I D D A V K K G H L Q K H N I
acgagagaaattatagggaactatagggagaatggacctaatggggatgtcaaggaactt
T R E I I G N Y R E N G P N G D V K E L
gccttggccatatctgatcgagtcaccgccgttggctgcggactaactacttggcaggat
A L A I S D R V T A V G C G L T T W Q D
ggagcaaaggctcgcgcacttcttacgtgtaacttctcctcgcagaacactcggggtcga
G A K A R A L L T C N F S S Q N T R G R
cctgtctacaaaatcggcaatagtcctggcgaaaagtgcatcgagaaggatgaaacgtat
P V Y K I G N S P G E K C I E K D E T Y
aaaaacttgtgccctgctactgaacctatcgaccctaataagtctaactagcgtcatgta
K N L C P A T E P I D P N K S N - R H V
tctatgtatataaataaaattgaagtgtctgtctgtaatataaaacaactgtcacttatt
S M Y I N K I E V S V C N I K Q L S L I
gagcgcaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
E R K K K K K K K K K
实施例二:制备姚虻唾液腺蛋白酶tabfiblysin:
一、姚虻唾液腺的解剖,匀浆与处理
姚虻解剖的方法如下:用小剪刀将虫体沿背中线剪开,放入4℃含0.15M NaClpH7.2的0.01M磷酸盐缓冲液中浸泡,挑取唾液腺,放入含上述缓冲液的烧杯中存于-20℃,解剖完毕后10000rpm离心10min,上清继续存放于-20℃,沉淀用玻璃匀浆器在冰上充分匀浆后10000rpm/min离心10min,合并两次离心上清,冻干并取部分样品水溶后用Sephadex G-25脱盐,冻干。
二、分离纯化的每一个步骤都用水解纤维蛋白原检测方法进行活性跟踪。
第一步,Sephadex G-75凝胶过滤:姚虻唾液腺匀浆液冻干粉溶解于0.05MTris-HCl+0.1M NaCl,pH7.2的缓冲液,上样于Sephadex-75(Pharmacia产品)凝胶过滤柱(1000mm长,26mm直径),用同样缓冲液洗脱,收集活性成分。
第二步,FPLC Resource S离子交换层析:Sephadex G-75凝胶过滤得到的活性成分峰,冻干溶解于水,于0.05M Tris-HCl pH 8.3缓冲液透析12hr;上样于Resource S柱,用一个0-0.5M NaCl的线性梯度进行洗脱,纯化得到纤维蛋白原水解酶。该步操作在AKTA Purifier FPLC系统中进行。
实施例三:姚虻唾液腺蛋白酶的药理实验:
一、纤维蛋白原水解活性检测
取10μL浓度为2mg/mL的纤维蛋白原(溶于含有150mM NaCl的50mMTris-HCl,pH7.4缓冲液)与样品于37℃保温24hr后,进行12%SDS-PAGE还原电泳分析。
二、血小板聚集抑制实验
富血浆小板聚集(PRP)抑制实验:健康人血小板用血浆稀释至2.5×108个/mL。取富血浆血小板300μL,加入适量样品保温5min后,添加ADP诱导聚集,记录5min血小板聚集情况。
聚集抑制率(I)的计算:
I=B/A×100%
A=激动剂所能达到的最大聚集(本文为透光率,%);
B=样品作用后加入激动剂所能达到的最大聚集。
三、出血活性检测
将样品溶解到生理盐水中,对小白鼠进行皮下注射,24小时后,剥离小鼠皮肤,观察内皮出血斑的大小。以生理盐水做对照。
姚虻唾液腺蛋白酶的药理实验表明:姚虻唾液腺蛋白酶tabfiblysin具有显著的水解纤维蛋白原和抑制血小板聚集的作用。姚虻唾液腺蛋白酶tabfiblysin能作为制备治疗血栓性疾病药物的被应用。
姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用.ST25SEQUENCE LISTING
<110>中国科学院昆明动物研究所
<120>姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用
<130>1
<160>2
<170>PatentIn version 3.3
<210>1
<211>872
<212>DNA
<213>Tabacus yao Macquart
<400>1
atgacttcca taccggtgtc cagcttttta cttgcggcct tagtactaca atacgccact 60
agcgacgcag ttaactactg tagattgcct tgtcgagggg ataattacca tgtgggctgt 120
ggtgagccag cgtatgccca ggaatgtggg caaagtccaa gaactcgcga gttattgaag 180
gagcatagaa atgagatttt gtcgaagatc aacgatgtgc gagaccatgt ggccaaggga 240
tcatggggac taccagtggc agcccgaatg aaagttgttg tatgggatgc ggaactcgct 300
ggtttagcca aacgacatac aaagggatgc gttggagaga cacatgcgtg tcgaaacaca 360
gaacgtttct ggttgccagg tcaactaaac ttcaaatact ccggcgacaa gctaccccgc 420
attaaggaac ttattgatga tgctgtcaaa aaaggccact tgcagaagca taatattacg 480
agagaaatta tagggaacta tagggagaat ggacctaatg gggatgtcaa ggaacttgcc 540
ttggccatat ctgatcgagt caccgccgtt ggctgcggac taactacttg gcaggatgga 600
gcaaaggctc gcgcacttct tacgtgtaac ttctcctcgc agaacactcg gggtcgacct 660
gtctacaaaa tcggcaatag tcctggcgaa aagtgcatcg agaaggatga aacgtataaa 720
aacttgtgcc ctgctactga acctatcgac cctaataagt ctaactagcg tcatgtatct 780
atgtatataa ataaaattga agtgtctgtc tgtaatataa aacaactgtc acttattgag 840
cgcaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 872
<210>2
<211>255
<212>PRT
<213>Tabacus yao Macquart
<400>2
Met Thr Ser Ile Pro Val Ser Ser Phe Leu Leu Ala Ala Leu Val Leu
1 5 10 15
Gln Tyr Ala Thr Ser Asp Ala Val Asn Tyr Cys Arg Leu Pro Cys Arg
20 25 30
Gly Asp Asn Tyr His Val Gly Cys Gly Glu Pro Ala Tyr Ala Gln Glu
35 40 45
Cys Gly Gln Ser Pro Arg Thr Arg Glu Leu Leu Lys Glu His Arg Asn
50 55 60
姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用.ST25
Glu Ile Leu Ser Lys Ile Asn Asp Val Arg Asp His Val Ala Lys Gly
65 70 75 80
Ser Trp Gly Leu Pro Val Ala Ala Arg Met Lys Val Val Val Trp Asp
85 90 95
Ala Glu Leu Ala Gly Leu Ala Lys Arg His Thr Lys Gly Cys Val Gly
100 105 110
Glu Thr His Ala Cys Arg Asn Thr Glu Arg Phe Trp Leu Pro Gly Gln
115 120 125
Leu Asn Phe Lys Tyr Ser Gly Asp Lys Leu Pro Arg Ile Lys Glu Leu
130 135 140
Ile Asp Asp Ala Val Lys Lys Gly His Leu Gln Lys His Asn Ile Thr
145 150 155 160
Arg Glu Ile Ile Gly Asn Tyr Arg Glu Asn Gly Pro Asn Gly Asp Val
165 170 175
Lys Glu Leu Ala Leu Ala Ile Ser Asp Arg Val Thr Ala Val Gly Cys
180 185 190
Gly Leu Thr Thr Trp Gln Asp Gly Ala Lys Ala Arg Ala Leu Leu Thr
195 200 205
Cys Asn Phe Ser Ser Gln Asn Thr Arg Gly Arg Pro Val Tyr Lys Ile
210 215 220
Gly Asn Ser Pro Gly Glu Lys Cys Ile Glu Lys Asp Glu Thr Tyr Lys
225 230 235 240
Asn Leu Cys Pro Ala Thr Glu Pro Ile Asp Pro Asn Lys Ser Asn
245 250 255
Claims (3)
1、姚虻蛋白酶tabfiblysin,其特征在于姚虻蛋白酶tabfiblysin是从姚虻唾液腺中分离得到的一种活性蛋白质,分子量27145.5道尔顿,其全序列一级结构为:
MTSIPVSSFLLAALVLQYATSDAVNYCRLPCRGDNYHVGCGEPAYAQECGQSPRTRELLKEHRNEILSK
INDVRDHVAKGSWGLPVAARMKVVVWDAELAGLAKRHTKGCVGETHACRNTERFWLPGQLNFKYSGDKL
PRIKELIDDAVKKGHLQKHNITREIIGNYRENGPNGDVKELALAISDRVTAVGCGLTTWQDGAKARALL
TCNFSSQNTRGRPVYKIGNSPGEKCIEKDETYKNLCPATEPIDPNKSN
2、姚虻蛋白酶tabfiblysin基因,其特征在于该基因由871个核苷酸组成,自5’端至3’端序列为:
atgacttccataccggtgtccagctttttacttgcggccttagtactacaatacgccact
agcgacgcagttaactactgtagattgccttgtcgaggggataattaccatgtgggctgt
ggtgagccagcgtatgcccaggaatgtgggcaaagtccaagaactcgcgagttattgaag
gagcatagaaatgagattttgtcgaagatcaacgatgtgcgagaccatgtggccaaggga
tcatggggactaccagtggcagcccgaatgaaagttgttgtatgggatgcggaactcgct
ggtttagccaaacgacatacaaagggatgcgttggagagacacatgcgtgtcgaaacaca
gaacgtttctggttgccaggtcaactaaacttcaaatactccggcgacaagctaccccgc
attaaggaacttattgatgatgctgtcaaaaaaggccacttgcagaagcataatattacg
agagaaattatagggaactatagggagaatggacctaatggggatgtcaaggaacttgcc
ttggccatatctgatcgagtcaccgccgttggctgcggactaactacttggcaggatgga
gcaaaggctcgcgcacttcttacgtgtaacttctcctcgcagaacactcggggtcgacct
gtctacaaaatcggcaatagtcctggcgaaaagtgcatcgagaaggatgaaacgtataaa
aacttgtgccctgctactgaacctatcgaccctaataagtctaactagcgtcatgtatct
atgtatataaataaaattgaagtgtctgtctgtaatataaaacaactgtcacttattgag
cgcaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
3、姚虻蛋白酶tabfiblysin的应用,其特征在于姚虻蛋白酶tabfiblysin能水解纤维蛋白原和抑制血小板聚集,且无出血活性,能作为制备治疗血栓性疾病药物的应用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200910094685XA CN101608176A (zh) | 2009-07-02 | 2009-07-02 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
CN2010800301210A CN103282091A (zh) | 2009-07-02 | 2010-06-14 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
EP10793558A EP2450440A4 (en) | 2009-07-02 | 2010-06-14 | FIBRINOGENOLYTIC ENZYME TABFIBLYSIN FROM THE BRAKE TABANUS YAO, GENE GENERATING THAT AND USE THEREOF |
PCT/CN2010/073987 WO2011000263A1 (zh) | 2009-07-02 | 2010-06-14 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
US13/381,685 US20120183525A1 (en) | 2009-07-02 | 2010-06-14 | Fibrinogenolytic enzyme tabfiblysin of horsefly, tabanus yao, encoding gene and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200910094685XA CN101608176A (zh) | 2009-07-02 | 2009-07-02 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101608176A true CN101608176A (zh) | 2009-12-23 |
Family
ID=41482086
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200910094685XA Pending CN101608176A (zh) | 2009-07-02 | 2009-07-02 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
CN2010800301210A Pending CN103282091A (zh) | 2009-07-02 | 2010-06-14 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800301210A Pending CN103282091A (zh) | 2009-07-02 | 2010-06-14 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120183525A1 (zh) |
EP (1) | EP2450440A4 (zh) |
CN (2) | CN101608176A (zh) |
WO (1) | WO2011000263A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011000263A1 (zh) * | 2009-07-02 | 2011-01-06 | 中国科学院昆明动物研究所 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
CN102071184A (zh) * | 2010-11-05 | 2011-05-25 | 中国科学院昆明动物研究所 | 牛虻抗血栓酶tablysin及其基因和应用 |
CN102732498A (zh) * | 2011-04-02 | 2012-10-17 | 秦引林 | 蛋白酶tablysin在制备抗肿瘤药物中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102559721B (zh) * | 2012-01-05 | 2013-03-20 | 哈尔滨师范大学 | 乌苏里蝮蛇毒fle基因、其编码蛋白及其真核表达产物的制备方法 |
CN113789319B (zh) * | 2021-10-14 | 2023-03-28 | 北京农学院 | 从蝇蛆中分离蛆激酶的方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451992B1 (en) * | 1998-08-20 | 2002-09-17 | Auburn University | Antithrobin nucleotides and proteins from horn fly |
CN101220091B (zh) * | 2008-01-31 | 2011-08-24 | 中国科学院昆明动物研究所 | 姚虻唾液腺免疫调节肽及其基因和应用 |
CN101608176A (zh) * | 2009-07-02 | 2009-12-23 | 中国科学院昆明动物研究所 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
-
2009
- 2009-07-02 CN CNA200910094685XA patent/CN101608176A/zh active Pending
-
2010
- 2010-06-14 EP EP10793558A patent/EP2450440A4/en not_active Withdrawn
- 2010-06-14 WO PCT/CN2010/073987 patent/WO2011000263A1/zh active Application Filing
- 2010-06-14 CN CN2010800301210A patent/CN103282091A/zh active Pending
- 2010-06-14 US US13/381,685 patent/US20120183525A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011000263A1 (zh) * | 2009-07-02 | 2011-01-06 | 中国科学院昆明动物研究所 | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 |
CN102071184A (zh) * | 2010-11-05 | 2011-05-25 | 中国科学院昆明动物研究所 | 牛虻抗血栓酶tablysin及其基因和应用 |
CN102071184B (zh) * | 2010-11-05 | 2013-03-20 | 中国科学院昆明动物研究所 | 牛虻抗血栓酶tablysin及其基因和应用 |
CN102732498A (zh) * | 2011-04-02 | 2012-10-17 | 秦引林 | 蛋白酶tablysin在制备抗肿瘤药物中的应用 |
CN102732498B (zh) * | 2011-04-02 | 2013-10-23 | 秦引林 | 蛋白酶tablysin在制备抗肿瘤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2450440A4 (en) | 2013-01-09 |
EP2450440A1 (en) | 2012-05-09 |
WO2011000263A1 (zh) | 2011-01-06 |
CN103282091A (zh) | 2013-09-04 |
US20120183525A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Venomic and transcriptomic analysis of centipede Scolopendra subspinipes dehaani | |
Brinkman et al. | Transcriptome and venom proteome of the box jellyfish Chironex fleckeri | |
Qinghua et al. | A catalog for transcripts in the venom gland of the Agkistrodon acutus: identification of the toxins potentially involved in coagulopathy | |
JPH11505418A (ja) | 膵臓由来セルピン | |
CN101608176A (zh) | 姚虻纤维蛋白原水解酶tabfiblysin及其基因和应用 | |
Wang et al. | Unique diversity of sting-related toxins based on transcriptomic and proteomic analysis of the jellyfish Cyanea capillata and Nemopilema nomurai (Cnidaria: Scyphozoa) | |
CN104387474B (zh) | 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用 | |
Sánchez et al. | Disintegrin, hemorrhagic, and proteolytic activities of Mohave rattlesnake, Crotalus scutulatus scutulatus venoms lacking Mojave toxin | |
Silva et al. | Activation of αMβ2-mediated phagocytosis by HF3, a P-III class metalloproteinase isolated from the venom of Bothrops jararaca | |
Leonel et al. | Bothrops jararaca snake venom inflammation induced in human whole blood: role of the complement system | |
CN102660565B (zh) | 尖吻蝮蛇血凝酶基因及其表达载体、宿主细胞和重组蛋白的制备方法 | |
CN102071184B (zh) | 牛虻抗血栓酶tablysin及其基因和应用 | |
Menezes et al. | Activation of leukocyte rolling by the cysteine-rich domain and the hyper-variable region of HF3, a snake venom hemorrhagic metalloproteinase | |
JP5345069B2 (ja) | 低出血性抗凝固性融合タンパク質の調製および使用 | |
CN103848914B (zh) | 一种具抗凝活性的菲牛蛭素多肽及其制备方法与用途 | |
CN108822196A (zh) | 一种促凝血多肽lgtx-f2及其应用 | |
CN108404119A (zh) | Fgf-21类似物的制备及在血栓治疗中的应用 | |
CN102757973A (zh) | 一种具有溶栓活性的海蚯蚓纤溶酶的cDNA序列及其氨基酸序列 | |
Howes et al. | The purification and partial characterisation of two novel metalloproteinases from the venom of the West African carpet viper, Echis ocellatus | |
CN102127168A (zh) | 一种髓样细胞表达激发受体-1的重组融合蛋白及其应用 | |
CN102199584B (zh) | 地鳖虫抗血栓酶Eupolytin1及其基因和应用 | |
CN101328478A (zh) | 一种具有抗血小板性栓塞活性的蛋白质及生产方法和应用 | |
CN106928334A (zh) | 约安巨马陆抗血栓肽Joannsin及其应用 | |
CN112375132A (zh) | 太湖白鱼来源的抗菌肽及其应用 | |
CN1850976A (zh) | 抑制血小板聚集和凝血酶活性的葡激酶衍生体和制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20091223 |